Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
32,211,835
-
Share change
-
-1,479,400
-
Total reported value
-
$47,030,607
-
Price per share
-
$1.46
-
Number of holders
-
47
-
Value change
-
-$3,467,928
-
Number of buys
-
17
-
Number of sells
-
26
Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS as of Q4 2018
As of 31 Dec 2018,
NABRIVA THERAPEUTICS PLC - SHS was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,211,835 shares.
The largest 10 holders included
Vivo Capital, LLC, Novo Holdings A/S, ORBIMED ADVISORS LLC, FRAZIER MANAGEMENT LLC, WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, Aisling Capital Management LP, Rock Springs Capital Management LP, DIMENSIONAL FUND ADVISORS LP, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
47
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.